L
6.29
0.02 (0.32%)
| Previous Close | 6.27 |
| Open | 6.22 |
| Volume | 649,556 |
| Avg. Volume (3M) | 1,242,656 |
| Market Cap | 459,090,304 |
| Price / Book | 4.09 |
| 52 Weeks Range | |
| Earnings Date | 23 Mar 2026 |
| Diluted EPS (TTM) | -3.31 |
| Total Debt/Equity (MRQ) | 10.67% |
| Current Ratio (MRQ) | 3.41 |
| Operating Cash Flow (TTM) | -88.00 M |
| Levered Free Cash Flow (TTM) | -50.43 M |
| Return on Assets (TTM) | -42.89% |
| Return on Equity (TTM) | -80.65% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Lexeo Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
-1.5
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -5.0 |
| Average | -1.50 |
|
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 121.45% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 25.00 (Raymond James, 297.46%) | Buy |
| Median | 17.00 (170.27%) | |
| Low | 10.00 (HC Wainwright & Co., 58.98%) | Buy |
| Average | 17.33 (175.52%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 8.27 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 13 Jan 2026 | 17.00 (170.27%) | Buy | 7.43 |
| HC Wainwright & Co. | 13 Jan 2026 | 10.00 (58.98%) | Buy | 7.43 |
| Raymond James | 18 Dec 2025 | 25.00 (297.46%) | Buy | 9.96 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February |
| 27 Jan 2026 | Announcement | Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics |
| 12 Jan 2026 | Announcement | Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy |
| 08 Jan 2026 | Announcement | Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy |
| 22 Dec 2025 | Announcement | Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |